bio-rad laboratories (nyse: bio and biob) offers a broad range of innovative tools and services to the life science research and clinical diagnostics markets. founded in 1952, bio-rad has a global team of more than 7,600 employees and serves more than 100,000 research and industry customers worldwide through the company's global network of operations. throughout its existence, bio-rad has built strong customer relationships that advance scientific research and development efforts and support the introduction of new technology used in the growing fields of genomics, proteomics, drug discovery, food safety, medical diagnostics, and more. based in hercules, ca, bio-rad has operations worldwide.
Company profile
Ticker
BIO, BIO.B
Exchange
Website
CEO
Norman Schwartz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIO RAD LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
Bio-Rad Laboratories Pty Ltd • Bio-Rad Laboratories NV • Research Specialties for Laboratories NV • Bio-Rad Laboratórios Brasil Ltda. • DiaMed Latino-América S.A. • Bio-Rad Laboratories (Canada) Limited • Bio-Rad Laboratories (Shanghai) Co., Ltd. • Bio-Rad (Shanghai) Life Science Research • Wuxi BioCanal Nano Technology Co. Ltd. • Bio-Rad Laboratories (Suzhou) Co. Ltd. ...
IRS number
941381833
BIO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
10 Apr 24
DEF 14A
Definitive proxy
27 Mar 24
ARS
2023 FY
Annual report to shareholders
27 Mar 24
8-K
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
20 Mar 24
8-K
Regulation FD Disclosure
21 Feb 24
10-K
2023 FY
Annual report
16 Feb 24
8-K
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
15 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Departure of Directors or Certain Officers
7 Dec 23
10-Q
2023 Q3
Quarterly report
27 Oct 23
Transcripts
BIO
Earnings call transcript
2023 Q4
15 Feb 24
BIO
Earnings call transcript
2023 Q3
26 Oct 23
BIO
Earnings call transcript
2023 Q2
3 Aug 23
BIO
Earnings call transcript
2023 Q1
4 May 23
BIO
Earnings call transcript
2022 Q4
16 Feb 23
BIO
Earnings call transcript
2022 Q3
28 Oct 22
BIO
Earnings call transcript
2022 Q2
29 Jul 22
BIO
Earnings call transcript
2022 Q1
29 Apr 22
BIO
Earnings call transcript
2021 Q4
11 Feb 22
BIO
Earnings call transcript
2021 Q3
29 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 458.32 mm | 458.32 mm | 458.32 mm | 458.32 mm | 458.32 mm | 458.32 mm |
Cash burn (monthly) | (no burn) | 4.99 mm | (no burn) | 15.60 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | 33.20 mm | n/a | 103.73 mm | n/a | n/a |
Cash remaining | n/a | 425.11 mm | n/a | 354.59 mm | n/a | n/a |
Runway (months of cash) | n/a | 85.1 | n/a | 22.7 | n/a | n/a |
Institutional ownership, Q3 2023
76.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 453 |
Opened positions | 59 |
Closed positions | 57 |
Increased positions | 139 |
Reduced positions | 178 |
13F shares | Current |
---|---|
Total value | 6.61 tn |
Total shares | 18.46 mm |
Total puts | 65.30 k |
Total calls | 60.00 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 2.34 mm | $840.12 bn |
BLK Blackrock | 1.44 mm | $514.98 bn |
Veritas Asset Management | 1.11 mm | $399.15 bn |
Brown Advisory | 955.73 k | $342.58 bn |
STT State Street | 859.32 k | $308.02 bn |
Ubs Global Asset Management Americas | 574.53 k | $205.94 bn |
BAC Bank Of America | 496.64 k | $178.02 bn |
Geode Capital Management | 452.10 k | $161.70 bn |
Alliancebernstein | 434.75 k | $155.84 bn |
Millennium Management | 376.62 k | $135.00 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Crowley Michael | NQSO Bio-Rad A Common Stock | Grant | Acquire A | No | No | 343.76 | 3,535 | 1.22 mm | 3,535 |
8 Mar 24 | Schwartz Norman D | NQSO Bio-Rad A Common Stock | Grant | Acquire A | No | No | 343.76 | 14,137 | 4.86 mm | 14,137 |
8 Mar 24 | Last Andrew J. | NQSO Bio-Rad A Common Stock | Grant | Acquire A | No | No | 343.76 | 5,891 | 2.03 mm | 5,891 |
8 Mar 24 | Colleen Corey | NQSO Bio-Rad A Common Stock | Grant | Acquire A | No | No | 343.76 | 2,357 | 810.24 k | 2,357 |
News
96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?
18 Apr 24
Oncocyte Announces Partnership Agreement With Bio-Rad Laboratories On Global Launch Of Transplant Assay; Bio-Rad Expects To Make Equity Investment In Support Of Deal
11 Apr 24
Bio-Rad Laboratories Says Andrew Last, Executive Vice President And COO, Is Planning To Retire By Early September Of 2024
10 Apr 24
Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $365
3 Apr 24
Tech Stocks Ease On Hot PPI, Yields Rise, Microsoft, Amazon Snap 5-Week Positive Streak: What's Driving Markets Friday?
16 Feb 24
Press releases
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
11 Apr 24
Bio-Rad's Chief Operating Officer Andrew Last to Retire
10 Apr 24
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer
20 Mar 24
Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day
22 Feb 24
Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
24 Jan 24